首页 > 最新文献

European Clinical Respiratory Journal最新文献

英文 中文
Cytomegalovirus and Crohn's disease as competing causes of small bowel inflammation after double-lung transplantation. 巨细胞病毒和克罗恩病是双肺移植术后小肠炎症的竞争原因。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-26 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2594336
Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup

Background: Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure.

Case presentation: A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn's disease. The patient was commenced on standard biological therapy for Crohn's disease, resulting in marked clinical improvement and recovery.

Conclusion: This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn's disease and determining the primary driver of the clinical presentation.

背景:巨细胞病毒(CMV)感染仍然是实体器官移植后发病的重要原因,最常影响胃肠道。对于出现腹泻的移植受者,应考虑其他病因,如炎症性肠病(IBD)。抗病毒药物耐药性的出现对治疗提出了挑战,在治疗失败的情况下,对耐药性相关突变进行分子检测是必不可少的。病例介绍:一例肺移植受者慢性腹泻导致功能性肠衰竭。在肠道活检中发现巨细胞病毒感染,最初用两个疗程的缬更昔洛韦进行治疗。由于症状持续,进行了基因型分析,揭示了UL97突变赋予更昔洛韦耐药性。foscarnet、maribavir和letermovir序序治疗获得病毒学清除,但腹泻持续存在。小肠镜活检显示持续的粘膜炎症和微小的残余巨细胞病毒活性。这些发现与更昔洛韦耐药巨细胞病毒肠炎与新发克罗恩病共存一致。患者开始接受克罗恩病的标准生物治疗,临床明显改善和恢复。结论:该病例说明了将巨细胞病毒性肠炎与新发克罗恩病区分开来的诊断挑战,并确定了临床表现的主要驱动因素。
{"title":"Cytomegalovirus and Crohn's disease as competing causes of small bowel inflammation after double-lung transplantation.","authors":"Julie Hansen Niklassen, Christian Lodberg Hvas, Kristian Schønning, Kasper Sommerlund Moestrup, Marie Helleberg, Michael Perch, Elisabeth Bendstrup","doi":"10.1080/20018525.2025.2594336","DOIUrl":"10.1080/20018525.2025.2594336","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure.</p><p><strong>Case presentation: </strong>A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn's disease. The patient was commenced on standard biological therapy for Crohn's disease, resulting in marked clinical improvement and recovery.</p><p><strong>Conclusion: </strong>This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn's disease and determining the primary driver of the clinical presentation.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2594336"},"PeriodicalIF":1.4,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12667282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using the 'very brief advice'-method for referral to smoking cessation programs. 使用“非常简短的建议”方法转介到戒烟项目。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-21 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2591512
Mojtaba Saei, Ingeborg Farver-Vestergaard, Mads Holm Hansen, Peter Hjorth, Charlotta Pisinger, Anders Løkke

Introduction: Successful smoking cessation remains a challenge. The 'Very Brief Advice' (VBA) method is the recommended clinical practice in Denmark for referral to smoking cessation programs. This study examines how healthcare providers use the Very Brief Advice (VBA) method for smoking cessation, comparing trained and untrained staff and exploring overall referral activity at a large Danish Hospital.

Methods: A cross-sectional survey was conducted at a major hospital in the Region of Southern Denmark. HCPs reported sociodemographic and work-related information as well as their use of the VBA in daily practice. Practices of smoking cessation support beyond the VBA-method and hospital-level data on monthly referrals (May 2018 to May 2022) were assessed as a secondary objective.

Results: Between June and September 2021, a total of 1,572 (out of 3,998) HCPs with regular patient contact completed survey and were included in the study. Results show that mandatory VBA training was only undertaken by 35.6% of the participants and nearly half (46.6%) of all participants reported that they never/almost never used VBA in their daily practice. A larger proportion of nurses completed the training, compared to other HCPs. A larger proportion of outpatient staff completed the training, compared to staff in inpatient units. Referral data showed a decline in monthly VBA-referrals, dropping from 299 per months in 2018 to 96 in 2022.

Conclusion: The use of the mandatory VBA method in a larger Danish hospital is limited and declining. We observed low participation in VBA training and low utilization among HCPs. Significant adjustments and reassessment of the implementation effort are necessary.Trial registration: Not relevant.

成功戒烟仍然是一个挑战。“非常简短的建议”(VBA)方法是丹麦推荐的临床实践,用于转介戒烟计划。本研究考察了医疗保健提供者如何使用非常简短的建议(VBA)戒烟方法,比较了训练有素和未训练有素的工作人员,并探索了丹麦一家大型医院的整体转诊活动。方法:在丹麦南部地区的一家大医院进行横断面调查。医务人员报告了社会人口统计和工作相关信息,以及他们在日常实践中使用VBA的情况。除vba方法外的戒烟支持实践和每月转诊(2018年5月至2022年5月)的医院级数据作为次要目标进行评估。结果:在2021年6月至9月期间,共有1,572名(3998名)定期与患者接触的HCPs完成了调查并被纳入研究。结果显示,只有35.6%的参与者接受了强制性的VBA培训,近一半(46.6%)的参与者报告说他们在日常实践中从未或几乎从未使用过VBA。与其他医护人员相比,完成培训的护士比例更高。与住院人员相比,门诊人员完成培训的比例更大。转诊数据显示,每月vba转诊数量有所下降,从2018年的299例下降到2022年的96例。结论:强制性VBA法在丹麦大型医院的应用有限且呈下降趋势。我们观察到HCPs的VBA培训参与率和使用率较低。有必要对执行工作进行重大调整和重新评估。试验注册:不相关。
{"title":"Using the 'very brief advice'-method for referral to smoking cessation programs.","authors":"Mojtaba Saei, Ingeborg Farver-Vestergaard, Mads Holm Hansen, Peter Hjorth, Charlotta Pisinger, Anders Løkke","doi":"10.1080/20018525.2025.2591512","DOIUrl":"10.1080/20018525.2025.2591512","url":null,"abstract":"<p><strong>Introduction: </strong>Successful smoking cessation remains a challenge. The 'Very Brief Advice' (VBA) method is the recommended clinical practice in Denmark for referral to smoking cessation programs. This study examines how healthcare providers use the Very Brief Advice (VBA) method for smoking cessation, comparing trained and untrained staff and exploring overall referral activity at a large Danish Hospital.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted at a major hospital in the Region of Southern Denmark. HCPs reported sociodemographic and work-related information as well as their use of the VBA in daily practice. Practices of smoking cessation support beyond the VBA-method and hospital-level data on monthly referrals (May 2018 to May 2022) were assessed as a secondary objective.</p><p><strong>Results: </strong>Between June and September 2021, a total of 1,572 (out of 3,998) HCPs with regular patient contact completed survey and were included in the study. Results show that mandatory VBA training was only undertaken by 35.6% of the participants and nearly half (46.6%) of all participants reported that they never/almost never used VBA in their daily practice. A larger proportion of nurses completed the training, compared to other HCPs. A larger proportion of outpatient staff completed the training, compared to staff in inpatient units. Referral data showed a decline in monthly VBA-referrals, dropping from 299 per months in 2018 to 96 in 2022.</p><p><strong>Conclusion: </strong>The use of the mandatory VBA method in a larger Danish hospital is limited and declining. We observed low participation in VBA training and low utilization among HCPs. Significant adjustments and reassessment of the implementation effort are necessary.<b>Trial registration</b>: Not relevant.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2591512"},"PeriodicalIF":1.4,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12642889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of bronchoscopy after computed tomography in the diagnostic work-up of haemoptysis. 计算机断层扫描后支气管镜检查在咯血诊断中的价值。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-07 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2573588
Christian Kildegaard, Amanda D Juul, Ibrahim M Slaiman, Christian B Laursen, Arman Arshad, Vasiliki Panou

Introduction: Haemoptysis, a common symptom with a variety of aetiologies, requires a comprehensive diagnostic approach. Computed tomography of the thorax (CT) and bronchoscopy are crucial in this process. This study assesses the value of bronchoscopy in patients with haemoptysis and CT with no findings suspicious of malignancy.

Methods and materials: This study retrospectively assessed patients with haemoptysis referred between January 2019 and December 2022 to the Department of Respiratory Medicine, Odense University Hospital. All patients who underwent CT and subsequently bronchoscopy due to haemoptysis were included in the study. Patients were excluded if CT or bronchoscopy was not performed, as well as patients suspected of malignancy on CT. Data, including patient characteristics, medical history, haemoptysis progression, CT, bronchoscopy results, and clinical assessments, were collected with a six-month follow-up.

Results: A total of 469 patients were assessed for eligibility, of whom 306 were excluded, resulting in 163 eligible patients. There were 95 males (58.28%), and the mean age was 57.8 years (SD 14.48). Mild haemoptysis (92.02%) and longer than one week (63.80%) was the most common presentation. CT revealed abnormal findings in 77 (47.24%) patients and for 117 (71.78%) patients followed a bronchoscopy with no abnormal observations. No malignant findings were detected by bronchoscopy.

Conclusion: The findings of this study revealed that bronchoscopy did not identify malignant aetiology beyond the scope of CT. These findings combined with current evidence suggest minimal benefit of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients. Take Home Message The diagnostic approach for patients with haemoptysis typically includes computed tomography (CT) and bronchoscopy to exclude pulmonary malignancy. This study supports current evidence of minimal value of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients.

简介:咯血是一种常见的症状,有多种病因,需要综合诊断方法。胸部计算机断层扫描(CT)和支气管镜检查在此过程中至关重要。本研究评估支气管镜检查在咯血和CT检查未发现可疑恶性肿瘤的患者中的价值。方法和材料:本研究回顾性评估了2019年1月至2022年12月在欧登塞大学医院呼吸内科转诊的咯血患者。所有因咯血而接受CT和支气管镜检查的患者都被纳入研究。未行CT或支气管镜检查的患者以及CT上怀疑为恶性的患者均被排除。数据包括患者特征、病史、咯血进展、CT、支气管镜检查结果和临床评估,随访6个月。结果:共有469例患者被评估为合格,其中306例被排除,163例患者符合条件。男性95例(58.28%),平均年龄57.8岁(SD 14.48)。轻度咯血(92.02%)和超过一周(63.80%)是最常见的表现。77例(47.24%)患者CT显示异常,117例(71.78%)患者行支气管镜检查未见异常。支气管镜检查未发现恶性肿瘤。结论:本研究结果显示支气管镜检查不能识别CT范围以外的恶性病因。这些发现结合目前的证据表明,在这些患者的胸部恶性肿瘤诊断评估中,CT后支气管镜检查的益处很小。咯血患者的诊断方法通常包括计算机断层扫描(CT)和支气管镜检查,以排除肺部恶性肿瘤。本研究支持目前的证据,即在这些患者的胸部恶性肿瘤诊断评估中,CT后支气管镜检查的价值很小。
{"title":"Value of bronchoscopy after computed tomography in the diagnostic work-up of haemoptysis.","authors":"Christian Kildegaard, Amanda D Juul, Ibrahim M Slaiman, Christian B Laursen, Arman Arshad, Vasiliki Panou","doi":"10.1080/20018525.2025.2573588","DOIUrl":"10.1080/20018525.2025.2573588","url":null,"abstract":"<p><strong>Introduction: </strong>Haemoptysis, a common symptom with a variety of aetiologies, requires a comprehensive diagnostic approach. Computed tomography of the thorax (CT) and bronchoscopy are crucial in this process. This study assesses the value of bronchoscopy in patients with haemoptysis and CT with no findings suspicious of malignancy.</p><p><strong>Methods and materials: </strong>This study retrospectively assessed patients with haemoptysis referred between January 2019 and December 2022 to the Department of Respiratory Medicine, Odense University Hospital. All patients who underwent CT and subsequently bronchoscopy due to haemoptysis were included in the study. Patients were excluded if CT or bronchoscopy was not performed, as well as patients suspected of malignancy on CT. Data, including patient characteristics, medical history, haemoptysis progression, CT, bronchoscopy results, and clinical assessments, were collected with a six-month follow-up.</p><p><strong>Results: </strong>A total of 469 patients were assessed for eligibility, of whom 306 were excluded, resulting in 163 eligible patients. There were 95 males (58.28%), and the mean age was 57.8 years (SD 14.48). Mild haemoptysis (92.02%) and longer than one week (63.80%) was the most common presentation. CT revealed abnormal findings in 77 (47.24%) patients and for 117 (71.78%) patients followed a bronchoscopy with no abnormal observations. No malignant findings were detected by bronchoscopy.</p><p><strong>Conclusion: </strong>The findings of this study revealed that bronchoscopy did not identify malignant aetiology beyond the scope of CT. These findings combined with current evidence suggest minimal benefit of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients. Take Home Message The diagnostic approach for patients with haemoptysis typically includes computed tomography (CT) and bronchoscopy to exclude pulmonary malignancy. This study supports current evidence of minimal value of bronchoscopy subsequent to CT in the diagnostic evaluation of thoracic malignancy in these patients.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2573588"},"PeriodicalIF":1.4,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12599340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 修正。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-06 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2580853

[This corrects the article DOI: 10.1080/20018525.2025.2546677.].

[这更正了文章DOI: 10.1080/20018525.2025.2546677.]。
{"title":"Correction.","authors":"","doi":"10.1080/20018525.2025.2580853","DOIUrl":"10.1080/20018525.2025.2580853","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1080/20018525.2025.2546677.].</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2580853"},"PeriodicalIF":1.4,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12599339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma is associated with increased Streptococcus pneumoniae carriage in the upper airway: a systematic review and meta-analysis. 哮喘与上呼吸道肺炎链球菌携带增加相关:一项系统综述和荟萃分析
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-05 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2569129
Raeni Dwi Putri, Chrysanti Murad, Kuswandewi Mutyara

Background: Asthma is a chronic respiratory condition characterized by airway inflammation and hyperreactivity. Previous studies have suggested a potential association between asthma and bacterial colonization of the upper respiratory tract. This systematic review and meta-analysis aimed to compare bacterial carriage rates, specifically focusing on Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus, among individuals with and without asthma.

Methods: We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) in reporting this meta-analysis.

Results: A total of 619 records were initially identified, leading to the inclusion of eight studies that met predefined inclusion criteria. The pooled prevalence rates of bacterial carriage were analyzed using a fixed-effect model. The risk of bias assessment was conducted using the Newcastle-Ottawa Scale. A total of 5,399 subjects were included, comprising 1,572 (29.11%) individuals with asthma and 3,827 (70.88%) without asthma. The prevalence of S. pneumoniae carriage was significantly higher in individuals with asthma (30.8%, 95% CI: 19.5-42.1%) compared to those without (19.2%, 95% CI: 8.3-30%) with an odds ratio (OR) of 1.35 (95% CI: 1.10-1.66, p = 0.005; I2 = 29%). In contrast, H. influenzae carriage rates were similar between groups (18.6% in individuals with asthma vs. 21.4% with no asthma; OR = 0.93, p = 0.84; I2 = 0%). The prevalence of M. catarrhalis was low in individuals with asthma (4.7%), and the data for S. aureus was limited, showing a prevalence of 36.67% among individuals with asthma compared to 26.67% with no asthma.

Conclusion: This systematic review and meta-analysis showed that asthma may increase the risk of S. pneumoniae carriage. The similar carriage rates of H. influenzae between the two groups suggest distinct mechanisms of bacterial colonization, underscoring the need to further investigate asthma's role in predisposing individuals to specific bacterial infections.

背景:哮喘是一种以气道炎症和高反应性为特征的慢性呼吸系统疾病。先前的研究表明,哮喘与上呼吸道细菌定植之间存在潜在的联系。本系统综述和荟萃分析旨在比较哮喘患者和非哮喘患者的细菌携带率,特别关注肺炎链球菌、流感嗜血杆菌、卡他莫拉菌和金黄色葡萄球菌。方法:我们遵循系统评价和荟萃分析首选报告项目(PRISMA)报告本荟萃分析。结果:最初共识别了619条记录,最终纳入了8项符合预定义纳入标准的研究。采用固定效应模型分析细菌携带的总患病率。偏倚风险评估采用纽卡斯尔-渥太华量表进行。共纳入5399名受试者,其中哮喘患者1572人(29.11%),非哮喘患者3827人(70.88%)。哮喘患者携带肺炎链球菌的患病率(30.8%,95% CI: 19.5-42.1%)明显高于无哮喘患者(19.2%,95% CI: 8.3-30%),优势比(OR)为1.35 (95% CI: 1.10-1.66, p = 0.005; I2 = 29%)。相比之下,组间流感嗜血杆菌携带率相似(哮喘患者18.6% vs.无哮喘患者21.4%;OR = 0.93, p = 0.84; I2 = 0%)。哮喘患者卡他性分枝杆菌的患病率较低(4.7%),金黄色葡萄球菌的数据有限,哮喘患者的患病率为36.67%,而非哮喘患者的患病率为26.67%。结论:本系统综述和荟萃分析显示,哮喘可能增加肺炎链球菌携带的风险。两组之间相似的流感嗜血杆菌携带率表明细菌定植的不同机制,强调有必要进一步研究哮喘在使个体易患特定细菌感染中的作用。
{"title":"Asthma is associated with increased <i>Streptococcus pneumoniae</i> carriage in the upper airway: a systematic review and meta-analysis.","authors":"Raeni Dwi Putri, Chrysanti Murad, Kuswandewi Mutyara","doi":"10.1080/20018525.2025.2569129","DOIUrl":"10.1080/20018525.2025.2569129","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a chronic respiratory condition characterized by airway inflammation and hyperreactivity. Previous studies have suggested a potential association between asthma and bacterial colonization of the upper respiratory tract. This systematic review and meta-analysis aimed to compare bacterial carriage rates, specifically focusing on <i>Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis</i>, and <i>Staphylococcus aureus</i>, among individuals with and without asthma.</p><p><strong>Methods: </strong>We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) in reporting this meta-analysis.</p><p><strong>Results: </strong>A total of 619 records were initially identified, leading to the inclusion of eight studies that met predefined inclusion criteria. The pooled prevalence rates of bacterial carriage were analyzed using a fixed-effect model. The risk of bias assessment was conducted using the Newcastle-Ottawa Scale. A total of 5,399 subjects were included, comprising 1,572 (29.11%) individuals with asthma and 3,827 (70.88%) without asthma. The prevalence <i>of S. pneumoniae</i> carriage was significantly higher in individuals with asthma (30.8%, 95% CI: 19.5-42.1%) compared to those without (19.2%, 95% CI: 8.3-30%) with an odds ratio (OR) of 1.35 (95% CI: 1.10-1.66, <i>p</i> = 0.005; I<sup>2</sup> = 29%). In contrast, <i>H. influenzae</i> carriage rates were similar between groups (18.6% in individuals with asthma vs. 21.4% with no asthma; OR = 0.93, <i>p</i> = 0.84; I<sup>2</sup> = 0%). The prevalence of <i>M. catarrhalis</i> was low in individuals with asthma (4.7%), and the data for <i>S. aureus</i> was limited, showing a prevalence of 36.67% among individuals with asthma compared to 26.67% with no asthma.</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis showed that asthma may increase the risk of <i>S. pneumoniae</i> carriage. The similar carriage rates of <i>H. influenzae</i> between the two groups suggest distinct mechanisms of bacterial colonization, underscoring the need to further investigate asthma's role in predisposing individuals to specific bacterial infections.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2569129"},"PeriodicalIF":1.4,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12590569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145481098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autonomy preferences and behaviors towards asthma medication in online asthma education: a secondary analysis of a cluster randomized controlled trial in adults with asthma. 在线哮喘教育中对哮喘药物的自主偏好和行为:一项针对成人哮喘患者的聚类随机对照试验的二次分析
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-02 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2581331
Stefanie Eck, Andrea Baumgärtel, Alexander Hapfelmeier, Klaus Linde, Linda Sanftenberg, Stefanie Stark, Antonius Schneider

Objective: Education programs are essential to involve individuals with asthma in disease management and improve outcomes. We aimed to investigate the effects of a pilot-tested online asthma education program (eAEP) on autonomy preferences and medication behavior in adults with asthma in general practices.

Methods: We performed a pre-planned secondary analysis of a cluster randomized trial comparing the eAEP with usual care (UC) in terms of Asthma Knowledge Test (AKT) scores. The Autonomy Preference Index (API) was used to assess patients' preferences for information (information preference) and involvement in medical decisions (participation preference). Participants evaluated eight statements regarding medication behavior. Outcomes were analyzed at baseline and six months.

Results: A total of 108 asthma patients (mean age: 47 years, 59% female) were analyzed. Increases in AKT scores were substantially larger in intervention groups (7.9 (95% CI 4.9-10.8), p < 0.001). API subscale scores increased in intervention and control groups, but group-differences were not statistically significant (participation preference: 2.8 (95% CI -4.1-9.6), p = 0.421; information preference: 1.1 (95% CI -1.8-4.1), p = 0.471). There was a positive correlation between changes in AKT and participation preference (r = 0.27, p = 0.031), but not information preference scores (r = 0.08, p = 0.472). Regarding medication behavior, there were some improvements in individual items in intervention groups, but no consistent patterns indicating a clear influence of API scores.

Conclusions: The eAEP did not result in larger increases in autonomy preferences compared to UC, but indicated beneficial effects on some forms of medication behavior. Larger studies are required for further insights.

目的:教育项目对哮喘患者参与疾病管理和改善预后至关重要。我们的目的是调查一个试点测试的在线哮喘教育项目(eAEP)对普通哮喘成人患者自主偏好和用药行为的影响。方法:我们对一项分组随机试验进行了预先计划的二次分析,比较了eAEP与常规护理(UC)在哮喘知识测试(AKT)评分方面的差异。自主偏好指数(API)用于评估患者对信息的偏好(信息偏好)和参与医疗决策的偏好(参与偏好)。参与者评估了八项关于药物行为的陈述。在基线和6个月时分析结果。结果:共分析108例哮喘患者(平均年龄47岁,女性59%)。干预组AKT评分的增加幅度更大(7.9 (95% CI 4.9-10.8), p p = 0.421;信息偏好:1.1 (95% CI -1.8-4.1), p = 0.471)。AKT的变化与参与偏好呈正相关(r = 0.27, p = 0.031),与信息偏好得分呈正相关(r = 0.08, p = 0.472)。在用药行为方面,干预组在个别项目上有一定的改善,但没有一致的模式表明API评分有明显的影响。结论:与UC相比,eAEP并没有导致自主性偏好的更大增加,但对某些形式的药物行为有有益的影响。需要更大规模的研究来进一步了解。
{"title":"Autonomy preferences and behaviors towards asthma medication in online asthma education: a secondary analysis of a cluster randomized controlled trial in adults with asthma.","authors":"Stefanie Eck, Andrea Baumgärtel, Alexander Hapfelmeier, Klaus Linde, Linda Sanftenberg, Stefanie Stark, Antonius Schneider","doi":"10.1080/20018525.2025.2581331","DOIUrl":"10.1080/20018525.2025.2581331","url":null,"abstract":"<p><strong>Objective: </strong>Education programs are essential to involve individuals with asthma in disease management and improve outcomes. We aimed to investigate the effects of a pilot-tested online asthma education program (eAEP) on autonomy preferences and medication behavior in adults with asthma in general practices.</p><p><strong>Methods: </strong>We performed a pre-planned secondary analysis of a cluster randomized trial comparing the eAEP with usual care (UC) in terms of Asthma Knowledge Test (AKT) scores. The Autonomy Preference Index (API) was used to assess patients' preferences for information (information preference) and involvement in medical decisions (participation preference). Participants evaluated eight statements regarding medication behavior. Outcomes were analyzed at baseline and six months.</p><p><strong>Results: </strong>A total of 108 asthma patients (mean age: 47 years, 59% female) were analyzed. Increases in AKT scores were substantially larger in intervention groups (7.9 (95% CI 4.9-10.8), <i>p</i> < 0.001). API subscale scores increased in intervention and control groups, but group-differences were not statistically significant (participation preference: 2.8 (95% CI -4.1-9.6), <i>p</i> = 0.421; information preference: 1.1 (95% CI -1.8-4.1), <i>p</i> = 0.471). There was a positive correlation between changes in AKT and participation preference (<i>r</i> = 0.27, <i>p</i> = 0.031), but not information preference scores (<i>r</i> = 0.08, <i>p</i> = 0.472). Regarding medication behavior, there were some improvements in individual items in intervention groups, but no consistent patterns indicating a clear influence of API scores.</p><p><strong>Conclusions: </strong>The eAEP did not result in larger increases in autonomy preferences compared to UC, but indicated beneficial effects on some forms of medication behavior. Larger studies are required for further insights.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2581331"},"PeriodicalIF":1.4,"publicationDate":"2025-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12581774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A patient-centred approach to malignant pleural effusion. 以病人为中心的恶性胸腔积液治疗方法。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-11-01 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2580788
Matthew Shorthose, Rebecca Crook, Rahul Bhatnagar

Background: Malignant pleural effusion (MPE) occurs in up to 20% of malignancies, most commonly from a breast or pulmonary primary. It confers a poor prognosis, with a median survival of less than a year, and the mainstay in treatment has previously been achieving pleurodesis.

Aims and methods: This review provides an overview of the most up to date literature for the treatment of MPE using a PubMed search, with a focus on patient-centred care.

Results: There is increased focus on outpatient management and control of symptoms for patients with MPE, allowing more in-depth conversations to be had over what individual patient goals are. The development of new approaches such as indwelling pleural catheters (IPC) and local anaesthetic thoracoscopy (LAT) also increase the options available. When manging the complexities of MPE, such as non-expansile lung and septated effusions, various approaches can be taken to treat them including fibrinolytics and IPC.

Discussion: The treatment of MPE has changed in the last 15 years to focus on outpatient management and symptom control. Careful discussions must be undertaken on a patient-by-patient basis.

背景:恶性胸腔积液(MPE)发生在高达20%的恶性肿瘤中,最常见于乳房或肺部原发。它的预后很差,中位生存期不到一年,以前的主要治疗方法是实现胸膜减压。目的和方法:本综述通过PubMed检索对MPE治疗的最新文献进行了概述,重点关注以患者为中心的护理。结果:对MPE患者的门诊管理和症状控制的关注有所增加,允许就个体患者目标进行更深入的对话。诸如留置胸膜导管(IPC)和局部麻醉胸腔镜(LAT)等新方法的发展也增加了可用的选择。当处理MPE的复杂性时,如肺非扩张性和分离性积液,可采取多种方法治疗,包括纤溶和IPC。讨论:在过去的15年里,MPE的治疗已经改变,重点放在门诊管理和症状控制上。必须在逐个病人的基础上进行认真的讨论。
{"title":"A patient-centred approach to malignant pleural effusion.","authors":"Matthew Shorthose, Rebecca Crook, Rahul Bhatnagar","doi":"10.1080/20018525.2025.2580788","DOIUrl":"10.1080/20018525.2025.2580788","url":null,"abstract":"<p><strong>Background: </strong>Malignant pleural effusion (MPE) occurs in up to 20% of malignancies, most commonly from a breast or pulmonary primary. It confers a poor prognosis, with a median survival of less than a year, and the mainstay in treatment has previously been achieving pleurodesis.</p><p><strong>Aims and methods: </strong>This review provides an overview of the most up to date literature for the treatment of MPE using a PubMed search, with a focus on patient-centred care.</p><p><strong>Results: </strong>There is increased focus on outpatient management and control of symptoms for patients with MPE, allowing more in-depth conversations to be had over what individual patient goals are. The development of new approaches such as indwelling pleural catheters (IPC) and local anaesthetic thoracoscopy (LAT) also increase the options available. When manging the complexities of MPE, such as non-expansile lung and septated effusions, various approaches can be taken to treat them including fibrinolytics and IPC.</p><p><strong>Discussion: </strong>The treatment of MPE has changed in the last 15 years to focus on outpatient management and symptom control. Careful discussions must be undertaken on a patient-by-patient basis.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2580788"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12581772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines. 胸膜间皮瘤的诊断和治疗进展:丹麦临床指南。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-10-29 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2580795
Vasiliki Panou, Jens Benn Sørensen, Jesper Ravn, Eric Santoni-Rugiu

Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleura. The PM diagnosis is challenging, both in terms of imaging, sampling of representative biopsies and pathological examination, and the treatment options are limited. The main aim of this article is to summarize the most recent advances in the diagnosis and management of PM as presented in the Danish clinical guidelines for PM. An expert task force consisting of a lung physician, a pathologist, an oncologist, and a thoracic surgeon conducted an ad hoc literature search during November 2023-July 2024, reviewed the evidence and developed the current clinical guidelines after reaching consensus. The article appraises the radiological modalities and biopsy techniques that are employed in PM diagnostics, provides a comprehensive overview of the evidence behind the PM histopathological and cytological diagnosis, and asserts the state of the art and novel developments of oncological, multimodal, and palliative PM treatment and follow-up that are portrayed in the Danish clinical guidelines.

胸膜间皮瘤是一种罕见的侵袭性胸膜恶性肿瘤。PM的诊断具有挑战性,无论是在影像学,代表性活检取样和病理检查方面,治疗选择有限。本文的主要目的是总结在PM的诊断和管理的最新进展,如在丹麦临床指南中提出的PM。由一名肺科医生、一名病理学家、一名肿瘤学家和一名胸外科医生组成的专家工作组在2023年11月至2024年7月期间进行了一项特别文献检索,审查了证据,并在达成共识后制定了当前的临床指南。本文评估了PM诊断中使用的放射学模式和活检技术,提供了PM组织病理学和细胞学诊断背后的证据的全面概述,并断言丹麦临床指南中所描述的肿瘤学,多模式和姑息性PM治疗和随访的最新进展。
{"title":"Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.","authors":"Vasiliki Panou, Jens Benn Sørensen, Jesper Ravn, Eric Santoni-Rugiu","doi":"10.1080/20018525.2025.2580795","DOIUrl":"10.1080/20018525.2025.2580795","url":null,"abstract":"<p><p>Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleura. The PM diagnosis is challenging, both in terms of imaging, sampling of representative biopsies and pathological examination, and the treatment options are limited. The main aim of this article is to summarize the most recent advances in the diagnosis and management of PM as presented in the Danish clinical guidelines for PM. An expert task force consisting of a lung physician, a pathologist, an oncologist, and a thoracic surgeon conducted an ad hoc literature search during November 2023-July 2024, reviewed the evidence and developed the current clinical guidelines after reaching consensus. The article appraises the radiological modalities and biopsy techniques that are employed in PM diagnostics, provides a comprehensive overview of the evidence behind the PM histopathological and cytological diagnosis, and asserts the state of the art and novel developments of oncological, multimodal, and palliative PM treatment and follow-up that are portrayed in the Danish clinical guidelines.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2580795"},"PeriodicalIF":1.4,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12573557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nordic Respiratory Academy: a historical note and reflection. 北欧呼吸学院:历史笔记和反思。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-10-27 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2577531
Amund Gulsvik, Per Sigvald Bakke, Knut Stavem

The first formal meeting of Nordic professors in pulmonary medicine took place in Gothenburg in December 1995. In Reykjavik in June 2003, the laws and statutes of the Nordic Respiratory Academy (NORA) were approved, and the first board was elected. NORA aimed to improve education, research, and clinical practice and became a meeting place for building friendships and exchange of ideas among academic teachers in pulmonary medicine in the Nordic region. The meetings initiated cooperative research among the university departments of respiratory medicine, and NORA reestablished the Nordic chest physicians' own pulmonary medical journal with roots in the Nordic region. Until 2025, 20 NORA meetings have been held. Its future depends on the perceived need for such a meeting place and academics that are willing to continue organizing and using this institution as a think tank.

1995年12月在哥德堡举行了北欧肺医学教授的第一次正式会议。2003年6月,在雷克雅未克,北欧呼吸学会(NORA)的法律和章程获得批准,并选出了第一届董事会。NORA旨在改善教育、研究和临床实践,并成为北欧地区肺医学学术教师之间建立友谊和交流思想的聚会场所。会议启动了各大学呼吸医学院系之间的合作研究,NORA重新建立了北欧胸科医生自己的肺科医学杂志,并扎根于北欧地区。到2025年为止,已经举行了20次NORA会议。它的未来取决于人们对这样一个会议场所的需求,以及学者们是否愿意继续组织和利用这个机构作为智囊团。
{"title":"Nordic Respiratory Academy: a historical note and reflection.","authors":"Amund Gulsvik, Per Sigvald Bakke, Knut Stavem","doi":"10.1080/20018525.2025.2577531","DOIUrl":"10.1080/20018525.2025.2577531","url":null,"abstract":"<p><p>The first formal meeting of Nordic professors in pulmonary medicine took place in Gothenburg in December 1995. In Reykjavik in June 2003, the laws and statutes of the Nordic Respiratory Academy (NORA) were approved, and the first board was elected. NORA aimed to improve education, research, and clinical practice and became a meeting place for building friendships and exchange of ideas among academic teachers in pulmonary medicine in the Nordic region. The meetings initiated cooperative research among the university departments of respiratory medicine, and NORA reestablished the Nordic chest physicians' own pulmonary medical journal with roots in the Nordic region. Until 2025, 20 NORA meetings have been held. Its future depends on the perceived need for such a meeting place and academics that are willing to continue organizing and using this institution as a think tank.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2577531"},"PeriodicalIF":1.4,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12570218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the financial burden of asthma among young adults in Sweden. 估计瑞典年轻人哮喘的经济负担。
IF 1.4 Q3 RESPIRATORY SYSTEM Pub Date : 2025-10-07 eCollection Date: 2025-01-01 DOI: 10.1080/20018525.2025.2569135
Alma Holm Rovsing, Richard Ssegonja, Christer Janson, Anders Løkke, Rikke Ibsen, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Ulla Møller Weinreich, Kjell Erik Julius Håkansson

Introduction: The financial burden of asthma in young adults remains sparsely investigated. Our study aims to estimate the Swedish national financial burden of asthma in adults aged 18-45 using nationwide databases.

Methods: The financial burden of asthma in Sweden was estimated using the Swedish burden of disease, cost of medical care, and sick leave utilization data from 2022, together with healthcare consumption estimates from a nationwide burden of asthma study (data from 2014 to 2018). Costs were calculated as total costs and excess costs compared to matched controls.

Results: The total annual financial burden for individuals with asthma was €3,572 per patient, divided into primary care (€929), secondary care (€1,137), medicine (€605), and sick leave transfers (€902). When compared to an age-, sex-, cohabitation-status-, and residence-matched control group, an annual excess cost of €2,299 (2,288-2,310) per patient with asthma was found. When stratified according to disease severity, patients at GINA 2020 Step 2 incurred the lowest annual cost at €2,916 (2,960-3,092), whereas GINA 2020 Step 5 represented the highest annual cost at €6,697 (6,559-6,793). Pooling the total mean costs for all young Swedish adults with ICS-treated asthma (n = 88,898) revealed an excess annual financial burden of €204,375,739, of which 39% (€ 80,150,137) were sick leave transfers.

Conclusion: Asthma in Sweden is associated with a substantial financial burden from both direct costs and asthma-related sick leave compared to matched controls, and the pooled excess burden of ICS-treated asthma in young adults exceeded €200,000,000 annually.

引言:年轻人哮喘的经济负担仍然很少调查。我们的研究旨在使用全国数据库估计瑞典18-45岁成人哮喘的国家经济负担。方法:使用瑞典疾病负担、医疗保健成本和2022年的病假利用数据,以及来自全国哮喘负担研究(2014年至2018年数据)的医疗保健消费估算,估算瑞典哮喘的经济负担。成本计算为总成本和超额成本与匹配控制相比较。结果:哮喘患者的年度总经济负担为每位患者3,572欧元,分为初级保健(929欧元)、二级保健(1,137欧元)、药品(605欧元)和病假转移(902欧元)。与年龄、性别、同居状态和居住匹配的对照组相比,每位哮喘患者每年的额外费用为2299欧元(2288 - 2310欧元)。当根据疾病严重程度进行分层时,GINA 2020步骤2的患者的年费用最低,为2,916欧元(2,960-3,092),而GINA 2020步骤5的年费用最高,为6,697欧元(6,559-6,793)。汇总所有患有ics治疗哮喘的瑞典年轻成年人(n = 88,898)的总平均费用显示,每年的额外经济负担为204,375,739欧元,其中39%(80,150,137欧元)是病假转会费。结论:与匹配对照相比,瑞典的哮喘与直接费用和哮喘相关病假带来的巨大经济负担有关,并且ics治疗的年轻成人哮喘的总额外负担每年超过2亿欧元。
{"title":"Estimating the financial burden of asthma among young adults in Sweden.","authors":"Alma Holm Rovsing, Richard Ssegonja, Christer Janson, Anders Løkke, Rikke Ibsen, Ole Hilberg, Vibeke Backer, Charlotte Suppli Ulrik, Ulla Møller Weinreich, Kjell Erik Julius Håkansson","doi":"10.1080/20018525.2025.2569135","DOIUrl":"10.1080/20018525.2025.2569135","url":null,"abstract":"<p><strong>Introduction: </strong>The financial burden of asthma in young adults remains sparsely investigated. Our study aims to estimate the Swedish national financial burden of asthma in adults aged 18-45 using nationwide databases.</p><p><strong>Methods: </strong>The financial burden of asthma in Sweden was estimated using the Swedish burden of disease, cost of medical care, and sick leave utilization data from 2022, together with healthcare consumption estimates from a nationwide burden of asthma study (data from 2014 to 2018). Costs were calculated as total costs and excess costs compared to matched controls.</p><p><strong>Results: </strong>The total annual financial burden for individuals with asthma was €3,572 per patient, divided into primary care (€929), secondary care (€1,137), medicine (€605), and sick leave transfers (€902). When compared to an age-, sex-, cohabitation-status-, and residence-matched control group, an annual excess cost of €2,299 (2,288-2,310) per patient with asthma was found. When stratified according to disease severity, patients at GINA 2020 Step 2 incurred the lowest annual cost at €2,916 (2,960-3,092), whereas GINA 2020 Step 5 represented the highest annual cost at €6,697 (6,559-6,793). Pooling the total mean costs for all young Swedish adults with ICS-treated asthma (<i>n</i> = 88,898) revealed an excess annual financial burden of €204,375,739, of which 39% (€ 80,150,137) were sick leave transfers.</p><p><strong>Conclusion: </strong>Asthma in Sweden is associated with a substantial financial burden from both direct costs and asthma-related sick leave compared to matched controls, and the pooled excess burden of ICS-treated asthma in young adults exceeded €200,000,000 annually.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"12 1","pages":"2569135"},"PeriodicalIF":1.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Clinical Respiratory Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1